Cutaneous leishmaniosis (CL) is a parasitic disease in animals and human with no satisfactory treatments and vaccination. Rapamycin is a potent inhibitor of mammalian target of rapamycin (mTOR) with various applications. Here, the effect of rapamycin alone or in combination with two other drugs, namely amphotericin B (AmB) and glucantime, was investigated against Leishmania tropica infection. In vitro viability and electron microscopy evaluation of the parasites showed detrimental changes in their appearance and viability. Treatment with clinically relevant dose of rapamycin (10.2 μg/dose) is able to control the parasite load in BALB/c mice infected with L. tropica. Furthermore, the cytokine profiles showed significant polarization towards Th1 immune response. Surprisingly, combination therapy with either AmB or glucantime was not efficient. Rapamycin is showed an effective alternative therapy against leishmaniosis caused by L. tropica.

中文翻译：

---

雷帕霉素的抗leishmanial作用作为控制热带利什曼原虫感染的替代方法。

皮肤利什曼病（CL）是动物和人的寄生虫病，没有令人满意的治疗方法和疫苗接种。雷帕霉素是雷帕霉素（mTOR）哺乳动物靶标的有效抑制剂，具有多种应用。在此，研究了雷帕霉素单独或与其他两种药物（两性霉素B（AmB）和葡聚糖胺）联合使用对热带利什曼原虫感染的作用。寄生虫的体外生存力和电子显微镜评估显示其外观和生存力发生了有害变化。用临床相关剂量的雷帕霉素（10.2μg/剂量）治疗能够控制感染了热带乳杆菌的BALB / c小鼠的寄生虫负荷。此外，细胞因子概况显示出对Th1免疫反应的显着极化。出人意料的是，与AmB或葡聚糖时间联合治疗无效。